Literature DB >> 24279334

Zebrafish: a model vertebrate suitable for the analysis of human genetic disorders.

Satoshi Ota1, Atsuo Kawahara.   

Abstract

Zebrafish is a popular model vertebrate because of its conservation of a significant number of morphological and physiological processes in vertebrate organogenesis. A number of zebrafish mutants isolated from chemical mutagenesis screens exhibit characterized morphological defects that often resemble the symptoms of human genetic disorders. Recent innovations in genome-editing technologies, such as transcription activator-like effector nucleases (TALEN) and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, enable us to investigate the loss-of-function phenotypes of developmentally regulated genes in zebrafish. This review highlights recent advances in reverse genetic technologies for zebrafish and presents possible applications of zebrafish for the study of human genetic disorders.
© 2013 Japanese Teratology Society.

Entities:  

Keywords:  clustered regularly interspaced short palindromic repeats/Cas9; genome editing; model organism; transcription activator-like effector nuclease; zebrafish

Mesh:

Year:  2014        PMID: 24279334     DOI: 10.1111/cga.12040

Source DB:  PubMed          Journal:  Congenit Anom (Kyoto)        ISSN: 0914-3505            Impact factor:   1.409


  10 in total

1.  A method for CRISPR/Cas9 mutation of genes in fathead minnow (Pimephales promelas).

Authors:  Jennifer A Maki; Jenna E Cavallin; Kevin G Lott; Travis W Saari; Gerald T Ankley; Daniel L Villeneuve
Journal:  Aquat Toxicol       Date:  2020-03-02       Impact factor: 4.964

2.  An efficient platform for generating somatic point mutations with germline transmission in the zebrafish by CRISPR/Cas9-mediated gene editing.

Authors:  Yibo Zhang; Zhiwei Zhang; Wei Ge
Journal:  J Biol Chem       Date:  2018-03-02       Impact factor: 5.157

3.  Zebrafish have an ethanol-inducible hepatic 4-nitrophenol hydroxylase that is not CYP2E1-like.

Authors:  Jessica H Hartman; Jordan S Kozal; Richard T Di Giulio; Joel N Meyer
Journal:  Environ Toxicol Pharmacol       Date:  2017-07-10       Impact factor: 4.860

4.  Wild sex in zebrafish: loss of the natural sex determinant in domesticated strains.

Authors:  Catherine A Wilson; Samantha K High; Braedan M McCluskey; Angel Amores; Yi-lin Yan; Tom A Titus; Jennifer L Anderson; Peter Batzel; Michael J Carvan; Manfred Schartl; John H Postlethwait
Journal:  Genetics       Date:  2014-09-18       Impact factor: 4.562

5.  Comparative study of herbal plants on the phenolic and flavonoid content, antioxidant activities and toxicity on cells and zebrafish embryo.

Authors:  Hassan Fahmi Ismail; Zanariah Hashim; Wong Tet Soon; Nur Syukriah Ab Rahman; Ain Nabihah Zainudin; Fadzilah Adibah Abdul Majid
Journal:  J Tradit Complement Med       Date:  2017-01-16

6.  Modeling Neuronal Diseases in Zebrafish in the Era of CRISPR.

Authors:  Angeles Edith Espino-Saldaña; Roberto Rodríguez-Ortiz; Elizabeth Pereida-Jaramillo; Ataúlfo Martínez-Torres
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

7.  CRISPR/Cas9-mediated generation of biallelic F0 anemonefish (Amphiprion ocellaris) mutants.

Authors:  Laurie J Mitchell; Valerio Tettamanti; Justin S Rhodes; N Justin Marshall; Karen L Cheney; Fabio Cortesi
Journal:  PLoS One       Date:  2021-12-15       Impact factor: 3.240

Review 8.  Site-Specific Integration of Exogenous Genes Using Genome Editing Technologies in Zebrafish.

Authors:  Atsuo Kawahara; Yu Hisano; Satoshi Ota; Kiyohito Taimatsu
Journal:  Int J Mol Sci       Date:  2016-05-13       Impact factor: 5.923

Review 9.  Zebrafish as a Model for Drug Screening in Genetic Kidney Diseases.

Authors:  Jochen Gehrig; Gunjan Pandey; Jens H Westhoff
Journal:  Front Pediatr       Date:  2018-06-28       Impact factor: 3.418

10.  Efficient Production and Identification of CRISPR/Cas9-generated Gene Knockouts in the Model System Danio rerio.

Authors:  Erin L Sorlien; Mary A Witucki; Joseph Ogas
Journal:  J Vis Exp       Date:  2018-08-28       Impact factor: 1.355

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.